<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04994249</url>
  </required_header>
  <id_info>
    <org_study_id>60657</org_study_id>
    <secondary_id>1R61NS118651-01A1</secondary_id>
    <nct_id>NCT04994249</nct_id>
  </id_info>
  <brief_title>Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation</brief_title>
  <official_title>Diagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify diagnostic and prognostic biomarker signatures of recovery versus having&#xD;
      persisting high-impact chronic pain and functional disability in adults with Chronic&#xD;
      Musculoskeletal Pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our overall goal is to discover and validate diagnostic and prognostic biomarkers for&#xD;
      musculoskeletal high-impact chronic pain. Chronic pain represents a public health crisis that&#xD;
      affects 50-100 million Americans and costs over $500 billion dollars annually. Chronic&#xD;
      musculoskeletal pain conditions comprise 70-80% of all chronic pain. The highest-need and&#xD;
      most impacted patients are those with high-impact chronic pain (affecting ~20 million&#xD;
      Americans), or pain associated with substantially restricted work, social, and self-care&#xD;
      activities for six or more months. Chronic pain-and high-impact chronic pain in particular-is&#xD;
      often treated with prescription opioids, and is linked to opioid-use disorder.&#xD;
      Multidisciplinary chronic pain treatments show incomplete recovery at the population level.&#xD;
      However, subgroups of individuals completely respond, do not change, or even worsen following&#xD;
      pain management. Thus, robust and validated diagnostic and prognostic biomarkers are needed&#xD;
      to identify those with high-impact chronic pain and determine the trajectory of outcome&#xD;
      (i.e., recovery versus persistence), respectively. Such biomarkers are essential to develop&#xD;
      safer, more effective patient-specific treatment strategies, particularly for those who are&#xD;
      refractory to current treatment options.&#xD;
&#xD;
      Many factors have been shown to be (1) diagnostic for the severity and impact of chronic pain&#xD;
      or (2) prognostic of the trajectory of chronic pain, including those that are related to the&#xD;
      central nervous system (CNS; structure, function), psychosocial (e.g., anxiety,&#xD;
      catastrophizing, social isolation), sensory (e.g., temporal summation, conditioned pain&#xD;
      modulation),1functional (e.g., accelerometry), multiomic (e.g., immune, microbiome), and&#xD;
      demographic. However, these studies are limited by (1) association rather than predictive&#xD;
      validity; (2) small sample sizes; (3) homogenous populations limiting external validity; and&#xD;
      (4) single modality factors. As chronic pain is a biopsychosocial condition, we need to&#xD;
      measure broadly across these multiple dimensions; the most valuable insights will be gained&#xD;
      by understanding not only individual pieces of data, but the relationships among them.&#xD;
      Recognizing the critical need for rapid, valid, and clinically useful breakthroughs in&#xD;
      signature discovery for risk- and treatment-stratification and novel therapeutic targets for&#xD;
      chronic pain, as called for in the HEAL initiative, we aim to discover reliable, validated&#xD;
      diagnostic and prognostic biomarker signatures of musculoskeletal high-impact chronic pain by&#xD;
      integrating CNS, multiomic, sensory, functional, psychosocial, and demographic domains.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 5, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Interference:</measure>
    <time_frame>6 months after baseline assessment</time_frame>
    <description>Pain Interference using Patient-Reported Outcome Measurement Information System (PROMIS)-Pain Interference on a T score (mean: 50; standard deviation: 10) and Graded Chronic Pain Scale (GCPS)</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Musculoskeletal Pain</condition>
  <condition>Pain</condition>
  <condition>Pain, Chronic</condition>
  <condition>Joint Pain</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood for Multiomics and Stool for Microbiome&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Musculoskeletal high-impact chronic pain.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Inclusion criteria: Adults (18-80 years; ~64% female expected based on clinic&#xD;
             distribution) with chronic MSP as categorized by the World Health Organization (WHO).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Chronic musculoskeletal pain (MSP) explained by inflammatory disease (e.g.,&#xD;
             rheumatoid arthritis, lupus) or CP with a primary diagnosis other than chronic MSP&#xD;
             (e.g., neuropathic pain), (2) significant cognitive impairment, (3) MRI&#xD;
             contraindication, (4) medical or psychiatric problems interfering with the study, (5)&#xD;
             current medicolegal factors (e.g., open disability claim), (6) plans for surgery&#xD;
             during the study, (7) pregnancy and (8) Children under the age of 18 will not be&#xD;
             included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Mackey, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Cunniffe Marcy, MSBH</last_name>
    <phone>6507216931</phone>
    <email>acmarcy@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Cunniffe Marcy, MSBH</last_name>
      <phone>650-721-6931</phone>
      <email>acmarcy@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Sean Mackey, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Von Korff M, Scher AI, Helmick C, Carter-Pokras O, Dodick DW, Goulet J, Hamill-Ruth R, LeResche L, Porter L, Tait R, Terman G, Veasley C, Mackey S. United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. J Pain. 2016 Oct;17(10):1068-1080. doi: 10.1016/j.jpain.2016.06.009. Epub 2016 Jul 1.</citation>
    <PMID>27377620</PMID>
  </reference>
  <reference>
    <citation>Kutch JJ, Labus JS, Harris RE, Martucci KT, Farmer MA, Fenske S, Fling C, Ichesco E, Peltier S, Petre B, Guo W, Hou X, Stephens AJ, Mullins C, Clauw DJ, Mackey SC, Apkarian AV, Landis JR, Mayer EA; MAPP Research Network. Resting-state functional connectivity predicts longitudinal pain symptom change in urologic chronic pelvic pain syndrome: a MAPP network study. Pain. 2017 Jun;158(6):1069-1082. doi: 10.1097/j.pain.0000000000000886.</citation>
    <PMID>28328579</PMID>
  </reference>
  <reference>
    <citation>Ung H, Brown JE, Johnson KA, Younger J, Hush J, Mackey S. Multivariate classification of structural MRI data detects chronic low back pain. Cereb Cortex. 2014 Apr;24(4):1037-44. doi: 10.1093/cercor/bhs378. Epub 2012 Dec 17.</citation>
    <PMID>23246778</PMID>
  </reference>
  <reference>
    <citation>Brown JE, Chatterjee N, Younger J, Mackey S. Towards a physiology-based measure of pain: patterns of human brain activity distinguish painful from non-painful thermal stimulation. PLoS One. 2011;6(9):e24124. doi: 10.1371/journal.pone.0024124. Epub 2011 Sep 13.</citation>
    <PMID>21931652</PMID>
  </reference>
  <reference>
    <citation>Feinstein AB, Sturgeon JA, Darnall BD, Dunn AL, Rico T, Kao MC, Bhandari RP. The Effect of Pain Catastrophizing on Outcomes: A Developmental Perspective Across Children, Adolescents, and Young Adults With Chronic Pain. J Pain. 2017 Feb;18(2):144-154. doi: 10.1016/j.jpain.2016.10.009. Epub 2016 Nov 5.</citation>
    <PMID>27825857</PMID>
  </reference>
  <reference>
    <citation>Bhandari RP, Feinstein AB, Huestis SE, Krane EJ, Dunn AL, Cohen LL, Kao MC, Darnall BD, Mackey SC. Pediatric-Collaborative Health Outcomes Information Registry (Peds-CHOIR): a learning health system to guide pediatric pain research and treatment. Pain. 2016 Sep;157(9):2033-2044. doi: 10.1097/j.pain.0000000000000609.</citation>
    <PMID>27280328</PMID>
  </reference>
  <reference>
    <citation>Sharifzadeh Y, Kao MC, Sturgeon JA, Rico TJ, Mackey S, Darnall BD. Pain Catastrophizing Moderates Relationships between Pain Intensity and Opioid Prescription: Nonlinear Sex Differences Revealed Using a Learning Health System. Anesthesiology. 2017 Jul;127(1):136-146. doi: 10.1097/ALN.0000000000001656.</citation>
    <PMID>28614083</PMID>
  </reference>
  <reference>
    <citation>Karayannis NV, Baumann I, Sturgeon JA, Melloh M, Mackey SC. The Impact of Social Isolation on Pain Interference: A Longitudinal Study. Ann Behav Med. 2019 Jan 1;53(1):65-74. doi: 10.1093/abm/kay017.</citation>
    <PMID>29668841</PMID>
  </reference>
  <reference>
    <citation>Sturgeon JA, Dixon EA, Darnall BD, Mackey SC. Contributions of physical function and satisfaction with social roles to emotional distress in chronic pain: a Collaborative Health Outcomes Information Registry (CHOIR) study. Pain. 2015 Dec;156(12):2627-2633. doi: 10.1097/j.pain.0000000000000313.</citation>
    <PMID>26230739</PMID>
  </reference>
  <reference>
    <citation>Goodin BR, Bulls HW, Herbert MS, Schmidt J, King CD, Glover TL, Sotolongo A, Sibille KT, Cruz-Almeida Y, Staud R, Fessler BJ, Redden DT, Bradley LA, Fillingim RB. Temporal summation of pain as a prospective predictor of clinical pain severity in adults aged 45 years and older with knee osteoarthritis: ethnic differences. Psychosom Med. 2014 May;76(4):302-10. doi: 10.1097/PSY.0000000000000058.</citation>
    <PMID>24804882</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sean Mackey</investigator_full_name>
    <investigator_title>Chief, Division of Pain Medicine Director, Stanford Systems Neuroscience and Pain Lab</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

